Medicine and Dentistry
Lipoprotein
100%
Low Density Lipoprotein Cholesterol
100%
Therapeutic Agent
100%
Monoclonal Antibody
100%
Hypercholesterolemia
100%
Lipoprotein Metabolism
100%
Antisense Oligonucleotide
100%
Hypertriglyceridemia
100%
Hypolipemia
100%
Triglyceride-Rich Lipoprotein
100%
Oligonucleotide Targeting
100%
Molecular Metabolism
100%
Evinacumab
100%
Messenger RNA
100%
Angiopoietin
100%
Biochemistry, Genetics and Molecular Biology
Blood Lipids
100%
Lipoprotein
100%
Angiopoietin
100%
Genome Editing
50%
Oligonucleotide
50%
Monoclonal Antibody
50%
Hypercholesterolemia
50%
Antisense
50%
Preclinical Study
50%
Hypertriglyceridemia
50%
Lipoprotein Metabolism
50%
Triglyceride-Rich Lipoprotein
50%
Molecular Metabolism
50%
Messenger RNA
50%
Low-Density Lipoprotein
50%
Immunology and Microbiology
Lipid Blood Level
100%
Lipoprotein
100%
Angiopoietin
100%
Monoclonal Antibody
50%
Antisense
50%
Preclinical Study
50%
Gene Editing
50%
Lipoprotein Metabolism
50%
Evinacumab
50%
Low-Density Lipoprotein
50%
Triglyceride-Rich Lipoprotein
50%
Keyphrases
Lipoprotein Levels
100%
Angiopoietin-like
100%
ANGPTL3
100%
Plasma Lipids
25%
Therapeutic Target
12%
Gene Editing
12%
Clinical Efficacy
12%
Monoclonal Antibody
12%
Low-density Lipoprotein Cholesterol (LDL-C)
12%
Vaccination
12%
Therapeutic Agents
12%
Hypercholesterolemia
12%
Antisense Oligonucleotides
12%
Preclinical Stage
12%
Hypertriglyceridemia
12%
Molecular Characteristics
12%
Phase 1 Trial
12%
Lipoprotein Metabolism
12%
Clinical Development
12%
Triglyceride-rich Lipoproteins
12%
Editing Strategies
12%
Vupanorsen
12%
ANGPTL3 Deficiency
12%
Evinacumab
12%
Familial Combined Hypolipidemia
12%
Pharmacology, Toxicology and Pharmaceutical Science
Lipoprotein
100%
Angiopoietin
100%
Triacylglycerol
33%
Monoclonal Antibody
33%
Hypercholesterolemia
33%
Antisense Oligonucleotide
33%
Hypolipemia
33%
Low Density Lipoprotein Cholesterol
33%
Hypertriglyceridemia
33%
Oligonucleotide Targeting
33%
Evinacumab
33%
Messenger RNA
33%